Commission Regulation (EC) No 1299/2005 of 8 August 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol   (Text with EEA relevance)

9.8.2005 EN Official Journal of the European Union L 206/4
COMMISSION REGULATION (EC) No 1299/2005
of 8 August 2005
amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol
(Text with EEA relevance)
THE COMMISSION OF THE EUROPEAN COMMUNITIES
,
Having regard to the Treaty establishing the European Community,
Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), and in particular Article 2 and the third paragraph of Article 4 thereof,
Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,
Whereas:
(1) All pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals should be evaluated in accordance with Regulation (EEC) No 2377/90.
(2) Phenoxymethylpenicillin has been included in Annex I to Regulation (EEC) No 2377/90 for porcine for muscle, liver and kidney. The entry should be extended for these target tissues and in addition for skin and fat to poultry excluding animals from which eggs are produced for human consumption.
(3) Phoxim has been included in Annex I to Regulation (EEC) No 2377/90 for muscle, kidney and fat for ovine excluding animals from which milk is produced for human consumption and for porcine for muscle, liver, kidney and for skin and fat. That substance has also been included in Annex III to that Regulation for chicken awaiting completion of scientific studies. These studies have now been completed and phoxim should therefore be inserted in Annex I to that Regulation.
(4) Norgestomet has been included in Annex III to Regulation (EEC) No 2377/90 for bovine awaiting completion of scientific studies. These studies have now been completed and norgestomet should therefore be inserted in Annex I to that Regulation.
(5) The substance thiamphenicol is included in Annex I to Regulation (EEC) No 2377/90 for bovine and chicken excluding animals from which eggs are produced for human consumption. In order to allow for the completion of scientific studies for the extension to cover porcine species, thiamphenicol should be included in Annex III to that Regulation.
(6) Regulation (EEC) No 2377/90 should be amended accordingly.
(7) An adequate period should be allowed before the applicability of this Regulation in order to enable Member States to make any adjustment which may be necessary in the light of this Regulation to the marketing authorisations granted in accordance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (2).
(8) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,